Freenome

The first liquid biopsy company that will clear FDA approvals for cancer diagnostics, with leading sensitivity and specificity. Freenome is revolutionizing early cancer detection with its cutting-edge multiomics test, an innovative fusion of tumor and non-tumor biomarkers, synthesized through advanced machine learning algorithms